Prostate Cancer Therapies: SBRT & 5DCT Advances

Here’s a summary of the research being presented by UCLA radiation oncology team at the conference,based on the provided text:

1. 5D Computed Tomography (5DCT) for Lung ‍Tumors:

* Presenter: Not explicitly named in the text.
* ⁣ ⁣ Focus: Improved imaging for lung tumor patients who breathe irregularly.5DCT accounts for ⁤breathing motion in 3D, providing clearer images for better radiation planning.
* Key Finding: 5DCT accurately defines tumor size and motion, and is reliable for most patients, even with variable breathing.
* Presentation Time/Location: Monday, Sept.29 at 3:10pm PDT in Room ‍155/157.

2. MRI-guided Prostate SBRT with/without Adaptive Dose Painting:

* Presenter: Dr. Travis Courtney
* Focus: ⁣Comparing standard MRI-guided ‍SBRT to an adaptive approach that boosts radiation to the tumor while⁢ reducing it to surrounding tissue.
* ‍ Key Finding: Adaptive dose painting led to higher acute side effects (urinary & bowel) as reported by physicians,but similar patient-reported quality of life.
* Presentation Time/Location: Monday, Sept. 29 at 8:30am⁣ PDT⁤ in Room 307/308.

3.Sexual Function After MRI-Guided⁢ Prostate SBRT (MIRAGE Trial):

* Presenter: dr. Jonathan Massachi
* Focus: assessing the impact of MRI-guided vs. CT-guided SBRT on sexual function in prostate‍ cancer patients.
* Key Finding: A significant decline in sexual function was observed in nearly one-third of men in both groups two years after treatment, despite MRI guidance.
* presentation Time/Location: Monday, ⁣Sept. 29 at 8:20am ⁤PDT in Room 307/308.

4. Postoperative SBRT for Head and Neck⁣ Cancer:

* Presenter: Dr. Miriam Lane
* Focus: Evaluating the use of SBRT after surgery ⁣for ⁤head⁢ and neck ⁢cancer.
* Key Finding: SBRT was well-tolerated, but ⁤about half⁢ of patients experienced cancer recurrence within two years. Outcomes were similar for newly diagnosed and⁣ recurrent cases.
* Presentation Time/Location: Not explicitly stated in the text.